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the phenotypic heterogeneity of nevi
spili.
HRAS mutations have recently been
demonstrated in a number of hamarto-
matous cutaneous neoplasms including
epidermal nevi and nevus sebaceous
(Groesser et al., 2012; Hafner et al.,
2012; Levinsohn et al., 2012; Sun et al.,
2013). When these alterations occur
early in development or affect multiple
cell lineages, they can result in develop-
mental syndromes called ‘RASopathies,’
such as Schimmelpenning, epidermal
nevus syndrome, and phacomatosis pig-
mentokeratotica (Hafner and Groesser,
2013). The HRAS point mutation
(c.37G-4C, p.Gly13Arg), in particular,
appears to be overrepresented among
HRAS mutations in these cutaneous con-
genital conditions. This mutation allows
constitutive activation of RAS pathway
likely facilitating the development of
secondary neoplasms through accrual of
additional genetic alterations.
Our finding adds sporadic nevus
spilus to the spectrum of congenital
cutaneous lesions that harbor activating
mutations in HRAS. In nevus spilus, we
speculate that the melanocytic neo-
plasms that arise from these tan patches
likely acquire additional genetic altera-
tions that enable progression. Indeed,
we have recently demonstrated such a
secondary change through amplification
of HRAS in Spitz nevi arising out of a
nevus spilus (Sarin et al., 2013). How-
ever, the secondary mutations that give
rise to the diverse spectrum of melano-
cytic neoplasms have not yet been
identified. The knowledge of the
genetic basis of nevus spilus represents
a further step towards understanding the
genetic etiology underlying melanocytic
neoplasms. In addition, these lesions
represent a unique opportunity to study
the genetic alterations that allow pro-
gression from a nevus spilus to a nevus
or melanoma in the setting of constitu-
tive RAS/MAPK activation.
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TO THE EDITOR
ATRX is a member of the SWI/SNF
family of chromatin remodelers, origin-
ally identified as mutated in patients
with Alpha Thalassemia/Mental Retar-
dation, X-linked syndrome. The protein
product contains several highly con-
served domains, including an ADD
(ATRX-DNMT3-DNMT3L) domain that
binds methylated histone H3 at lysine 9
and an ATPase domain responsible for
its remodeling activities (Ratnakumar
and Bernstein, 2013). Recently, whole-
genome sequencing studies identified
ATRX mutations in multiple tumors,
including those of neural crest cell
origin: neuroblastoma, low-grade glioma,
and glioblastoma (Heaphy et al., 2011a;
Jiao et al., 2011; Cheung et al., 2012;Accepted article preview online 27 January 2014; published online 27 February 2014
Abbreviations: ATRX, alpha thalassemia/mental retardation, X-linked; IHC, immunohistochemistry
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Kannan et al., 2012; Schwartzentruber
et al., 2012). ATRX alterations encom-
pass point mutations throughout the
coding region as well as large N-terminal
deletions. Although mechanistically
unclear, ATRX mutations result in loss
of protein as assessed by immuno-
histochemistry (IHC) and often corre-
late with alternative lengthening of
telomeres (ALT) (Heaphy et al., 2011a;
Cheung et al., 2012; Kannan et al.,
2012; Schwartzentruber et al., 2012).
To our knowledge, an investigation of
ATRX in cutaneous melanoma is cur-
rently lacking. Our previous studies
have demonstrated that decreased
expression of histone variant macroH2A
drives melanoma cell proliferation and
metastasis (Kapoor et al., 2010), and that
ATRX interacts with macroH2A to
negatively regulate its association with
chromatin (Ratnakumar et al., 2012).
Taken together with recent reports of
decreased ATRX protein in neural crest
cell–derived tumors, we hypothesized
that ATRX function might be compro-
mised in melanoma.
In order to test this hypothesis, we
performed IHC on a panel of 23 benign
nevi, 33 primary melanoma (X1.0 mm
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Figure 1. Loss of ATRX protein expression is associated with melanoma progression. (a) Immunohistochemistry (IHC) for ATRX in representative benign nevi,
thick primary, and metastatic melanoma tissue. Images were taken at  20 magnification; insets (bottom right) show nuclei at  40 magnification. Insets (top left)
show an ATRX-positive stain of endothelial cells within metastatic specimens. Bar¼100mm. (b) IHC scores of benign nevi and thick primary and metastatic
melanoma from two independent pathologists. Each tissue section was quantified based on number of positively stained cells (1–4) multiplied by stain intensity
(1–3) to generate a score. (c) Table summarizing number of total samples and average IHC score per lesion. (d) ATRX protein levels versus presence of ulceration in
primary melanoma specimens. All statistical significance assessed using the two-sided Mann–Whitney U-test, P-value indicated. Mean±SD.
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deep), and 25 metastatic melanoma
specimens that were formalin fixed and
paraffin embedded (FFPE) (Figure 1a and
c). Slides were evaluated by two derma-
topathologists in a blinded fashion
using a scoring system based on num-
ber of positive nuclei and staining
intensity (inter-rater correlation r¼
0.693, Po0.0001; see Supplementary
Methods online for details). As depicted
in Figure 1a, ATRX protein expression is
appreciably reduced with increased
malignancy. Benign nevi showed a
higher proportion and intensity of
nuclear staining when compared with
metastatic lesions (Figure 1a and b;
Po0.0001). Furthermore, ATRX protein
expression was reduced between benign
nevi and primary melanoma, with het-
erogeneous staining observed in the
latter (P¼0.0026; Figure 1a and b),
and between primary and metastatic
melanoma (P¼ 0.0113; Figure 1b).
This suggests a potential stepwise loss
of ATRX expression during melanoma
progression.
We further examined whether ATRX
levels in primary melanoma correlated
with clinicopathological predictors of
prognosis. ATRX staining did not corre-
late with depth of the lesion (data not
shown); however, the primary melano-
mas examined in our cohort were of a
Breslow thickness 41.0 mm (average
depth, 5.6 mm), and thus were quite
aggressive. We did, however, find an
inverse correlation with the presence of
ulceration, a poor prognostic factor
(Figure 1d). Because our study is
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Figure 2. ATRX mRNA levels are decreased in metastatic melanoma. (a) Illustration of ATRX with domains and five amplicons depicted (left). ATRX cDNA was
amplified as indicated for analysis of putative deletions in metastatic melanoma specimens (right). WM266-4 and U2OS were used as controls. (b) qRT-PCR
analysis of ATRX from fresh frozen benign nevi and metastatic melanoma lesions. N- and C-terminal primers were used. Melanoma specimens analyzed in a are
depicted in red and in c are highlighted in blue and numbered. Expression levels were normalized to GAPDH and statistical significance was derived using
unpaired Student’s t-test, P-values indicated. Mean±SD. (c) ATRX IHC in representative metastatic melanoma tissues from b. Images were taken at  20
magnification; insets (bottom right) show nuclei at  40 magnification. Bar¼100mm.
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retrospective with a small sample size,
we note that any correlations, or lack
thereof, are preliminary.
Because structural variations of ATRX
exist in neuroblastoma and osteosar-
coma (Cheung et al., 2012; Lovejoy
et al., 2012), we determined whether
such alterations are present in metastatic
melanoma. Using a technique to detect
structural variations of ATRX, we per-
formed qualitative reverse transcriptase
(RT)–PCR of cDNA derived from a
cohort of fresh frozen metastatic mela-
noma samples (n¼7). Owing to the
large ATRX-coding region, we amplified
the cDNA into five fragments ranging
from 1.5 to 2 kb pairs. Because ATRX is
located on the X chromosome, we
analyzed both male and female patients
for potential effects due to gene dosage.
Our analysis shows that the ATRX gene
product is intact in all metastatic mela-
nomas assayed, as evidenced by
appropriately sized bands within each
sample (Figure 2a). The cell line
WM266-4 derived from a melanoma
metastasis served as a positive control
for PCR amplicons, as it is devoid of
ATRX mutations (Cancer Cell Line Ency-
clopedia at http://cbioportal.org). The
osteosarcoma cell line U2OS, which
has large deletions of the ATRX locus
(Lovejoy et al., 2012), was used to ensure
that our assay worked effectively. This
analysis suggested that decreased ATRX
protein levels in metastatic melanoma
is unlikely to be the result of large
genomic alterations.
We next queried whether diminished
ATRX protein in metastatic disease
was due to transcriptional regulation.
We performed qPCR analysis on a
cohort of 18 fresh frozen benign nevi
and 20 metastatic melanoma tumors,
including those samples analyzed for
deletions (Figure 2a; indicated in red
in Figure 2b). Using both N- and
C-terminal primers for ATRX, we
found a statistically significant loss of
ATRX mRNA levels in metastatic mela-
noma as compared with benign tissue
(Po0.0001; Figure 2b). We next per-
formed IHC on a subset of these tumors,
for which FFPE tissue was available
(indicated in blue in Figure 2b). The
level of ATRX protein indeed corrobo-
rated our qPCR findings (Figure 2c).
Collectively, these results indicate that
ATRX loss occurs, at least in part, by
transcriptional repression resulting in
loss of protein expression in late-stage
disease.
Collectively, we demonstrate that
ATRX loss correlates with melanoma
progression. Using two independent
cohorts (FFPE and fresh frozen; total of
119 tissues), we found a significant
decrease of both mRNA and protein
levels of ATRX in metastatic melanoma.
Although it remains to be tested in a
prospective study, ATRX may serve as a
biomarker to predict prognosis of dis-
ease. Although we did not find evidence
of large genomic alterations in a subset
of melanoma patients, we do not
exclude the possibility of ATRX muta-
tions in melanoma. In fact, a 4–7.5%
rate of mutation in cutaneous mela-
noma is reported by TCGA, Broad and
Yale studies (http://www.cbioportal.org).
Interestingly, these mutations are dis-
tributed throughout the ATRX-coding
region and do not correlate with
decreased mRNA levels (Supplemen-
tary Figure S1 online). This suggests
that multiple mechanisms underlie
ATRX dysregulation in melanoma—
transcriptional regulation as described
here, and point mutations that may
result in loss of protein expression, as
reported for other tumor types (Cheung
et al., 2012; Kannan et al., 2012;
Schwartzentruber et al., 2012).
Although ATRX staining did not anti-
correlate with macroH2A levels (data
not shown), we previously showed that
macroH2A is transcriptionally silenced
by DNA methylation in malignant mel-
anoma and thus might not be regulated
at the level of chromatin deposition
(Kapoor et al., 2010). The mechanism
by which ATRX transcription is sup-
pressed in melanoma may also be
through epigenetic silencing (e.g., DNA
methylation or histone modifications),
or by microRNA-mediated regulation
(Pacurari et al., 2013). Finally, we
posit that investigating the chromatin
landscape of tumors that have lost
ATRX expression should provide
insights into the mechanism(s) by
which ATRX loss drives melanoma
progression.
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Transplantable Malignant Melanoma in LT.B6 Congenic
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in Humans
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TO THE EDITOR
The transplantable B16 melanoma
model has been used for decades and
continues to be used with various de-
grees of reproducibility in mice (Fidler,
1975). Melanocytic tumors or nevus-like
lesions were induced in two-stage
cutaneous chemical oncogenesis experi-
ments in various inbred strains of
mice (Bannasch and Goessner, 1994;
Sundberg et al., 1997; Maronpot et al.,
1999). Recently a number of genetically
engineered mouse models have been
generated to recapitulate the major
signaling pathways deregulated in
human melanoma, namely, the RAS–
RAF–MAPK, PI3K–AKT, CDK4–INK4A–
RB1, and ARF–TP53 pathways (reviewed
in the study by Damsky and Bosenberg
(2010) and Walker et al. (2011)).
These preclinical models have been
invaluable to delineate the relationship
between causative gene mutations
and molecularly targeted therapeutics;
however, there are no spontaneously
occurring melanocytic tumors in labo-
ratory mice to globally discover other
disrupted gene networks. Although
melanomas are relatively common in
humans and domestic animals exposed
to sunlight, the scarcity of spontaneous
melanomas in laboratory mice might be
the result of the mice never being expo-
sed to sunlight or artificial UVR under
normal husbandry conditions. Herein,
we report the finding of a spontaneous,
locally invasive, transplantable malig-
nant melanoma that resembles pigmen-
ted epithelioid melanocytoma (PEM),
formally known as the ‘‘animal/equine-
type’’ in humans (Zembowicz et al.,
2004).
We found a 172-day-old female
LT.B6 ‘‘line E’’ congenic mouse on
routine examination to have multiple
raised black nodules on the tail
(Figure 1a). Histopathology showed dif-
fusely and heavily pigmented dermal
a
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Figure 1. Clinical and histopathological features of LT.B6 congenic mouse. Multiple black nodules were
noted on the tail of a 172-day-old female mouse (a), scale bar¼7 mm; histologically showing heavily
pigmented dermal nodules (b), scale bar¼200mm; sparing the adnexae (c), scale bar¼ 50mm; surrounding
but not invading the tail nerves (d), scale bar¼ 100mm or the ventral coccygeal artery (e), bar¼50mm.
Accepted article preview online 29 January 2014; published online 6 March 2014
Abbreviations: CT, cycle threshold; LN, lymph node; Mitf, microphthalmia-associated transcription factor;
qRT-PCR, quantitative real-time reverse transcriptase–PCR; PEM, pigmented epithelioid melanocytoma;
Tyrp1, tyrosine-related protein 1
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